Abstract
Icofungipen is a cyclic beta-amino acid being development by PLIVA, under license from Bayer, for the potential oral treatment of fungal infection. As of September 2002, the first phase II efficacy study was underway.
MeSH terms
-
Animals
-
Antifungal Agents / adverse effects*
-
Antifungal Agents / chemical synthesis
-
Antifungal Agents / pharmacokinetics
-
Antifungal Agents / pharmacology*
-
Antifungal Agents / therapeutic use
-
Antifungal Agents / toxicity
-
Clinical Trials, Phase I as Topic
-
Clinical Trials, Phase II as Topic
-
Contraindications
-
Cycloleucine / adverse effects
-
Cycloleucine / analogs & derivatives*
-
Cycloleucine / chemical synthesis
-
Cycloleucine / pharmacokinetics
-
Cycloleucine / pharmacology
-
Cycloleucine / therapeutic use
-
Cycloleucine / toxicity
-
Humans
-
Mycoses / drug therapy*
-
Mycoses / microbiology
-
Structure-Activity Relationship
Substances
-
Antifungal Agents
-
Cycloleucine
-
2-amino-4-methylenecyclopentane-1-carboxylic acid